Clinical trials: Mental Depression
Major Depressive Disorder, Fibromyalgia
Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is…
- Conditions
- Major Depressive Disorder, Fibromyalgia, Diabetic Peripheral Neuropathic Pain, Generalized Anxiety Disorder
- Trial name
- NCT00071708
- Testing
- Duloxetine Hydrochloride
- Where
- 13 sites in Australia
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
This study will evaluate the efficacy and safety of ALKS 5461.
- Trial name
- NCT02218008
- Testing
- ALKS 5461
- Where
- 44 sites in United States, Canada and 2 more
- Volunteers
- 407 people
- Sponsor
- Alkermes, Inc.
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- MOONSTONE (NCT00320268)
- Testing
- Quetiapine fumarate
- Where
- 37 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.
- Trial name
- NCT03188185
- Testing
- ALKS 5461
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 278 people
- Sponsor
- Alkermes, Inc.
Depressive Disorder, Major
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and…
- Trial name
- VENTURA-LT (NCT05518149)
- Testing
- Aticaprant
- Where
- 234 sites in United States, Argentina and 19 more
- Volunteers
- 871 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06963021
- Testing
- NBI-1065845
- Where
- 35 sites in United States, Belgium and 5 more
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Depression - Major Depressive Disorder, Anxiety
Singula Phase 0.1 Primary Care Pilot
This prospective, single-arm, observational pilot study evaluates a clinical decision support system developed by Singula Health for use in primary care.
- Trial name
- NCT07834684
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Singula Health, Inc.
Depressive Disorder
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression
The purpose of the study is to evaluate the efficacy and safety of SR58611A in elderly patients with depression.The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in elderly…
- Trial name
- ZEPHIR (NCT00319709)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Finland and 3 more
- Volunteers
- 288 people
- Sponsor
- Sanofi
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD).
- Trial name
- NCT02431806
- Testing
- Levomilnacipran, Fluoxetine
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 552 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.
- Trial name
- NCT00042029
- Testing
- MK0869, aprepitant
- Volunteers
- 324 people
- Sponsor
- Merck Sharp & Dohme LLC
Seasonal Affective Disorder
Prevention of Seasonal Affective Disorder
This is a placebo controlled study evaluating the effectiveness of medication in preventing depressive episodes in subjects with a history of Seasonal Affective Disorder (SAD).
- Trial name
- NCT00046241
- Testing
- Extended-release bupropion hydrochloride
- Where
- 51 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults
This study is designed to evaluate the safety and efficacy of the Fisher Wallace Stimulator FW-200 to deliver Cranial Electrotherapy Stimulation (CES) for the treatment of moderate to severe Major Depressive Disorder (MDD) in…
- Trial name
- CES-MDD (NCT05384041)
- Testing
- Fisher Wallace Cranial Electrotherapy Stimulator (Active Device)
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- Fisher Wallace Laboratories
Major Depressive Disorder (MDD)
Validation of Accexible as a Tool for Screening and Monitoring Depression.
Major depressive disorder (MDD) is a chronic disease with a prevalence around 8-12% and is considered one of the most debilitating disease worldwide.
- Trial name
- NCT06044818
- Testing
- Accexible
- Where
- Spain
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Accexible
Postpartum Depression, Postnatal Depression
Phase 2 Clinical Trial of GH001 in Postpartum Depression
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 female participants with clinically diagnosed postpartum depression (PPD) will be included in this study.
- Trial name
- NCT05804708
- Testing
- GH001
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 10 people
- Sponsor
- GH Research Ireland Limited
Depressive Disorder, Depression
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- NCT01727726
- Testing
- Brexpiprazole, Seroquel XR
- Where
- 76 sites in United States, Canada and 5 more
- Volunteers
- 2,182 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of venlafaxine ER 75 mg/day (fixed dose) and venlafaxine ER 75 mg/day to 225 mg/day (flexible…
- Trial name
- NCT01441440
- Testing
- venlafaxine ER 75 mg/day (fixed dose), venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)
- Where
- 63 sites in Japan
- Volunteers
- 538 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Tools known as 'depression scales 'are widely used as assessments to evaluate a patient's response to treatment. The purpose of this study is the evaluation of the remission rates for patients with MDD.
- Trial name
- B2411003 (NCT00770289)
- Testing
- Cohort
- Where
- 3 sites in Greece
- Volunteers
- 851 people
- Sponsor
- Pfizer
Depressive Disorder, Major
Impact of Atypical Antipsychotic Therapy on Health Outcomes and Costs Among Patients With Major Depressive Disorder
The primary objective is to examine changes in pre/post-augmentation healthcare costs and resource utilization in patients diagnosed with major depressive disorder (MDD) who augment their current antidepressant therapy with an…
- Trial name
- NCT01145313
- Volunteers
- 501 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Anhedonia in Healthy Volunteers
The Effect of an Edible Algal Extract (Ulva Lactuca) on the Component of Depression in Healthy Volunteers With Anhedonia
The effects of the seaweed extract were evaluated on the animal model equivalent of depression compared with a control group treated with the carrier (spring water) and a reference group treated with Imipramine and showed…
- Trial name
- NCT03545399
- Testing
- Ulva Lactuca
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- CEN Biotech
Major Depressive Disorder
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.
- Trial name
- NCT03864614
- Testing
- SAGE-217
- Where
- 52 sites in United States
- Volunteers
- 1,515 people
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.